Investigational drug · Phase 2
KDS2010
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight, Obesity, Obese Patients.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "KDS2010"
First trial start
2025
Jul 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KDS2010", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight
- Obesity
- Obese Patients
- Mild Cognitive Impairment (MCI)
- Mild Dementia
- Alzheimer's Disease
Approved drugs for the same conditions: Obesity and weight management · Alzheimer's disease · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "KDS2010" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's DiseasePivotal-lookingRecruiting
NeuroBiogen Co., LtdIndustry
NCT07027072 · 114 participants (planned) · Start Aug 6, 2025 · Primary completion Jun 30, 2027
Drug: KDS2010; Placebo · For: Mild Cognitive Impairment (MCI); Mild Dementia; Alzheimer's Disease
Sites: Gwangju, South Korea; Guri-si, South Korea; Suwon, South Korea · 8 sites in all
NeuroBiogen Co., LtdIndustry
NCT07009171 · 75 participants (planned) · Start Jul 29, 2025 · Primary completion Jan 31, 2027
Drug: KDS2010; KDS2010 and 4 more · For: Overweight; Obesity; Obese Patients
Sites: Suwon, South Korea; Seoul, South Korea · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Oral KDS2010, a Monoamine Oxidase-B (MAO-B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO-B-Mediated Inflammation.
Woo DH, Jeon JH, Ryu HJ, et al. · J Neurochem 2025
- Astrocytic monoamine oxidase B (MAOB)-gamma-aminobutyric acid (GABA) axis as a molecular brake on repair following spinal cord injury.
Lee HY, Lee JM, Lee HL, et al. · Signal Transduct Target Ther 2025
- Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder.
Yoon S, Won W, Lee S, et al. · Signal Transduct Target Ther 2025
- KDS2010, a reversible MAO-B inhibitor, extends the lifetime of neural probes by preventing glial scar formation.
Chae U, Chun H, Lim J, et al. · Glia 2024
- Two weeks dose range-finding and four weeks repeated dose oral toxicity study of a novel reversible monoamine oxidase B inhibitor KDS2010 in cynomolgus monkeys.
Kim KT, Cho DW, Cho JW, et al. · Toxicol Res 2023
- Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA.
Sa M, Yoo ES, Koh W, et al. · Nat Metab 2023
Also in development for Overweight
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.